06/01/2026
New data alert!
UCB Biopharma and Biogen release positive Phase 3 date from the PHOENYCS GO study showing that when combined with standard care, investigational dapirolizumab pegol (DZP) significantly improved disease activity in patients with moderate-to-severe active systemic lupus erythematosus (SLE).
Learn more about the results: https://bit.ly/4dXB2MG